OPKO Health

OPK · Nasdaq · United States

Share price · OPK

$1.69+0.33 (+24.26%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.1M (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when OPK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 15 Oct 2026+17.5%
  2. 29 Jul 2026-17.3%
  3. 28 Jul 2026+33.1%
  4. 13 Jul 2026-8.9%

    Nothing announced by OPK that day or the session before.

  5. 28 May 2026+10.0%
  6. 20 May 2026+7.0%

    Nothing announced by OPK that day or the session before.

  7. 18 May 2026+2.7%
  8. 29 Apr 2026-8.3%
  9. 6 Apr 2026+3.5%

    Nothing announced by OPK that day or the session before.

  10. 2 Mar 2026+3.3%

Share of unusual movement by asset

For each asset, the share of OPK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Extended-release calcifediol (Rayaldee)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—37%
Sessions with no dated event—63%

Assets

(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
Vitamin D receptor (VDR), via conversion to calcitriolSmall molecule
Chronic Kidney Disease
Secondary Hyperparathyroidism
somatrogon(NGENLA)
Approved
Growth hormone receptorProtein / enzyme therapeutic
Growth Hormone Deficiency
Phase 1/2
GLP-1/glucagon receptor (dual)
MASH / NASH

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
October 2027 (1)
Extended-release calcifediol · RayaldeePhase 2CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
Est. primary completion 2027-10 · NCT07494045 · CT.gov ↗
What to watch
December 2027 (1)
OPK-88006Phase 1/2MASH
Est. primary completion 2027-12 · NCT07512427 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (21)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$65M$32M$403M$54M-$36M operating cash flowreport ↗
View 20 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$164M$33M$314M$8.4M-$44M operating cash flowreport ↗
2026-Q1$124M$29M$356M$55M-$19M operating cash flowreport ↗
2025-Q4$148M—$383M$31M-$26M operating cash flowreport ↗
2025-Q3$152M$30M$429M—-$35M operating cash flowreport ↗
2025-Q2$157M$30M$285M$148M-$83M operating cash flowreport ↗
2025-Q1$150M$31M$450M$68M-$35M operating cash flowreport ↗
2024-Q4$184M—$446M—-$44M operating cash flowreport ↗
2024-Q3$174M$29M$420M—-$77M operating cash flowreport ↗
2024-Q2$182M$24M$41M$10M-$26M operating cash flowreport ↗
2024-Q1$174M$22M$76M$82M-$36M operating cash flowreport ↗
2023-Q4$182M—$96M$66M-$38M operating cash flowreport ↗
2023-Q3$179M$19M$139M$84M$33M operating cash flowreport ↗
2023-Q2$265M$18M$108M$20M-$0.4M operating cash flowreport ↗
2023-Q1$238M$33M$111M$18M-$23M operating cash flowreport ↗
2022-Q4$185M—$153M$85M-$32M operating cash flowreport ↗
2022-Q3$180M$19M$181M$86M-$32M operating cash flowreport ↗
2022-Q2$310M$17M$210M$102M-$11M operating cash flowreport ↗
2022-Q1$329M$18M$102M$55M-$20M operating cash flowreport ↗
2021-Q4$401M—$135M$74M-$5.6M operating cash flowreport ↗
2021-Q3$386M$18M$149M—$33M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$607M$124M$383M$56M-$179M operating cash flowreport ↗

OPKO Health reported full-year 2025 revenue of $606.88M, down 14.9% YoY, with R&D spend of $124.03M, up 17.9% YoY. Cash and equivalents were $382.74M, and the company reported a net loss of $225.68M.

Management introduced 2026 guidance for total revenues of $125M–$140M in Q1 and $530M–$560M for the full year, with total costs and expenses of $170M–$180M and $725M–$750M, respectively, and R&D included in costs of $30M–$32M and $125M–$135M. Key developments included a new Regeneron collaboration for multispecific antibodies, completion of Merck’s Phase 1 Epstein-Barr virus vaccine trial, FDA clearance to proceed for MDX2301, Australian Phase 1 approval for MDX2003, ongoing advancement of MDX2001 and MDX2004, and an expanded Entera Bio partnership for an oral PTH tablet program.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$713M$105M$446M$13M-$183M operating cash flowreport ↗
2023-FY$864M$90M$96M$47M-$28M operating cash flowreport ↗
2022-FY$1.0B$74M$153M$82M-$95M operating cash flowreport ↗
2021-FY$1.8B$77M$135M$7.5M$38M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 6 purchases ($780K), 2 sales ($25K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-05PAGANELLI JOHN A · directorOpen-market sale4,426$1.78$8KForm 4
2026-11-05PAGANELLI JOHN A · directorOpen-market sale9,175$1.82$17KForm 4
2026-07-24Rubin Steven D · director, Executive VP-AdministrationTax withholding53,266$1.22$65KForm 4
2026-07-24Logal Adam · Sr. Vice President, CFOTax withholding53,266$1.22$65KForm 4
2026-06-18Yu Alice Lin-Tsing · directorAward / grant (derivative)30,000——Form 4
2026-06-18UPPALURI SUBBARAO V · directorAward / grant (derivative)80,000——Form 4
2026-06-18PFENNIGER RICHARD C JR · directorAward / grant (derivative)60,000——Form 4
2026-06-18PAGANELLI JOHN A · directorAward / grant (derivative)30,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 232 reporting institutions held 200.8M shares ($227.3M, 27.0% of shares outstanding).

#InstitutionSharesValue
1Rubric Capital Management LP47,791,243$54.5M
2BlackRock, Inc.36,232,223$41.3M
3VANGUARD PORTFOLIO MANAGEMENT LLC14,769,719$16.8M
4VANGUARD CAPITAL MANAGEMENT LLC14,499,164$16.5M
5GEODE CAPITAL MANAGEMENT, LLC11,301,501$12.9M
6STATE STREET CORP9,501,377$10.8M
7GOLDMAN SACHS GROUP INC7,675,026$8.7M
8UBS Group AG6,071,432$6.9M
9Whitefort Capital Management, LP4,253,340$4.8M
10NORTHERN TRUST CORP3,619,346$4.1M
11CHARLES SCHWAB INVESTMENT MANAGEMENT INC3,574,039$4.1M
12VANGUARD FIDUCIARY TRUST CO2,742,017$3.1M
13AWM Investment Company, Inc.2,100,000$2.4M
14CITADEL ADVISORS LLC2,079,547$2.4M
15DIMENSIONAL FUND ADVISORS LP1,560,000$1.8M